Slide 1: Q1 2018 Results
K Pharm Q1 2018 Results
Slide 2: Cautionary Note Regarding Presentation Information
Cautionary Note Regarding Presentation Information This presentation contains forward-looking statements, including statements about our plans to develop and commercialize our product candidates, our planned clinical trials for our prodrug product candidates, the timing of and our ability to obtain
Slide 3: Q1 2018 Results Call Participants
Q1 2018 Results Call Participants + Travis Mickle, Ph.D. - President & Chief Executive Officer + R. LaDuane Clifton, CPA - Chief Financial Officer, Secretary & Treasurer * Dan Cohen, M.A.L.S.— EVP, Government & Public Relations
Slide 4: Recent Development and Regulatory Updates
Recent Development and Regulatory Updates + Announced Positive, Topline Results from an Intravenously (IV) Administered KP415 Prodrug Human Abuse Potential Trial « Announced FDA Approval of APADAZ™ for the Short-Term Management of Acute Pain + Announced Positive Topline Results from KP415 PK Study i
Slide 5: Drug Liking VAS after IV Injection of KP415 Prodrug
Drug Liking VAS after IV Injection of KP415 Prodrug At the Moment Drug Liking VAS Scores —*-KP415 Prodrug —e-d-MPH HCI —e-Placebo VAS Score Time (hours) Note: d-MPH HCI = dexmethylphenidate hydrochloride Drug Liking was assessed on a bipolar scale (0 = Strong Disliking, 50 = Neutral, 100 = Strong Li
Slide 6: Key Abuse Endpoints after IV Injection of KP415 Prodrug
Key Abuse Endpoints after IV Injection of KP415 Prodrug Maximum Scores (Emax) m= KP415 Prodrug @d-MPH HCl = Placebo VAS Score Drug Liking Overall Drug Liking Note: d-MPH HCI = dexmethylphenidate hydrochloride Drug Liking and Overall Drug Liking were assessed on a bipolar scale (0 = Strong Disliking,
Slide 7: Key Abuse Endpoints after IV Injection of KP415 Prodrug
Key Abuse Endpoints after IV Injection of KP415 Prodrug Maximum Score (Emax) m= KP415 Prodrug md-MPH HCl = Placebo VAS Score Take Drug Again Note: d-MPH HCI = dexmethylphenidate hydrochloride Take Drug Again was assessed on a unipolar scale (0 = Definitely Not, 100 = Definitely Yes) Subjects receive
Slide 8: ADHD Prodrug Product Pipeline — Addressing Unmet Needs
ADHD Prodrug Product Pipeline — Addressing Unmet Needs KP415 — ADHD Product Candidate for Fast Onset and Longer Total Duration + Unmet needs identified by physicians in order of importance: o Duration of efficacy o Less abuse potential o Onset of efficacy + Extended release product candidate + Prodr
Slide 9: KemPharm Near-Term Product Candidates
KemPharm Near-Term Product Candidates Category, Candidate ADHD PAIN Potential Product Parent Drug Development Next NDA Status Milestone mite Submission Methylphenidate = PK + Efficacy KP415 (ER) Clinical Data Q1 2019 KP484 Methylphenidate Clinical PK + Efficacy 2019 (ER) Data EEE aS SSS Hydrocodone/
Slide 10: Q1 2018 Financial Results
Q1 2018 Financial Results * Q1 2018 net loss of $26.2M, or $1.77 per basic and diluted share, vs. Q1 2017 net loss of $16.3M, or $1.11 per basic and diluted share * Net loss for Q1 2018 was primarily due to loss from operations of $14.8M, net interest expense and other items of $1.7M, and non-cash f
Slide 11: KemPharm Expected Timelines
KemPharm Expected Timelines Product Event Date KP484 IND Filing 2017 v KP415 Initiate Pivotal Efficacy Study 2017 v Apadaz™ FDA Approval 02/23/18 v KP415/ KP484 IV Human Abuse Liability (HAL) Data Q2 2018 v KP415 Pivotal Efficacy Study Results Mid-2018 KP484 Initiate Pivotal Efficacy Study 2H 2018 K
Slide 12: Q1 2018 Results
K Pharm Q1 2018 Results